Sofosbuvir (CAS 1190307-88-0)
See product citations (1)
Alternate Names:
PSI-7977
CAS Number:
1190307-88-0
Molecular Weight:
529.45
Molecular Formula:
C22H29FN3O9P
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B polymerase, which is for viral replication. It works by being metabolized in the liver to form the active antiviral agent. Once inside the liver cells, it interferes with the enzyme that the hepatitis C virus uses to replicate its RNA. This disruption ultimately leads to a decrease in viral RNA levels and a reduction in the amount of hepatitis C virus. By interfering directly with the enzymatic machinery of the virus, Sofosbuvir effectively reduces the replication and proliferation of HCV. Its role in research centers on exploring the dynamics of viral suppression and understanding the molecular interactions between viral enzymes and antiviral agents.
Sofosbuvir (CAS 1190307-88-0) References
- Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. | Ferreira, AC., et al. 2017. Sci Rep. 7: 9409. PMID: 28842610
- Sofosbuvir use for yellow fever: a new perspective treatment. | Siqueira-Batista, R., et al. 2019. Pathog Glob Health. 113: 207-208. PMID: 31613184
- Amino-decorated mesoporous silica nanoparticles for controlled sofosbuvir delivery. | Mehmood, Y., et al. 2020. Eur J Pharm Sci. 143: 105184. PMID: 31846695
- Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. | Bojkova, D., et al. 2020. Cells. 9: PMID: 32316635
- Sofosbuvir as a potential option for the treatment of COVID-19. | Nourian, A. and Khalili, H. 2020. Acta Biomed. 91: 236-238. PMID: 32420958
- Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. | Simmons, B., et al. 2021. J Antimicrob Chemother. 76: 286-291. PMID: 33063117
- The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico. | Elfiky, AA., et al. 2022. Mol Divers. 26: 171-181. PMID: 33389441
- Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation. | Rey, E., et al. 2021. Clin Transl Med. 11: e275. PMID: 33463051
- Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. | Zein, AFMZ., et al. 2022. Postgrad Med J. 98: 509-514. PMID: 34103373
- Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients. | Rubino, C., et al. 2021. Expert Rev Gastroenterol Hepatol. 15: 1097-1105. PMID: 34338120
- Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. | Chuang, WL., et al. 2021. Am J Gastroenterol. 116: 1924-1928. PMID: 34465694
- Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials. | Hsu, CK., et al. 2022. Int J Antimicrob Agents. 59: 106545. PMID: 35134505
- High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection. | Liang, Z., et al. 2022. Antiviral Res. 199: 105274. PMID: 35247472
- Quantitative 31P-NMR for Purity Determination of Sofosbuvir and Method Validation. | Uchiyama, N., et al. 2022. Chem Pharm Bull (Tokyo). 70: 892-900. PMID: 36223954
- Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels. | Yao, X., et al. 2022. Cell. 185: 4801-4810.e13. PMID: 36417914
Inhibitor of:
Adenovirus-5 hexon, Alphavirus, ASF1A, CDV, Dengue Virus, DGUOK, DIMT1, FDC-SP, Flavivirus, Hep B preS1, Hep C cAg, Hep C NS5b, Hep C p21, HepC NS4a, HepC NS5b, Influenza A pb1, KHNYN, KIAA1305, La Crosse Virus G1, Liprin α4, LSm10, Measles M, Measles virus, Mengo 3DPol, Mx1, Norovirus, Rubella Virus gpE1, Rubella Virus structural glycoprotein, SLC17A (solute carrier family 17), SR-2C, St. Louis encephalitis, TMC7, V1RC19, and vCCI.Activator of:
Bunyavirus, Ebola virus VP40, Hep B eAg, Hep B preS2, Hep C NS4, Hep C NS5b, LALP70, and P2ry10.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sofosbuvir, 25 mg | sc-482362 | 25 mg | $143.00 |